US 8251982

I'll search for information on this patent and any associated litigation.

Let me search for any litigation or CAFC activity, and verify USPTO records.

Let me do a couple of targeted searches on litigation and CAFC activity.

Summary of US Patent 8,251,982 B2

Scope note on my searching: I searched the open web (Google Patents, Justia, FreePatentsOnline, PatentCenter references, and docket aggregators). I found no record of any litigation or Federal Circuit (CAFC) appeal involving US 8,251,982, and specifically no 2026 CAFC docket activity. I do not have direct API access to the USPTO PatentCenter or the CAFC docket system; my search was via general web sources. If a 2026 CAFC appeal exists, it is not surfacing in these results — treat "no litigation found" as an absence of evidence, not authoritative proof of non-existence. What follows is grounded in the patent's own front-matter and claim text from the Google Patents record.

---

Bibliographic Data

Assignment note: Assignment from Zaghetto and Marchesini to ASA S.R.L. was recorded 2006-07-21 (effective 2006-06-12), Reel/Frame 017973/0113. Maintenance fees were paid (4th, 8th, and 12th year, the latter with a late surcharge in 2024), consistent with the "Active" status.

---

Abstract (paraphrased)

The patent discloses apparatuses and methods for applying laser energy therapeutically — notably for relief of pain and/or inflammation in tissue. The core idea is synchronizing two spatially overlapping laser energy forms whose emission axes are closely positioned, together with defined emission modalities (power, activation time, activation period, pulse duration, pulse period, wavelength). This synchronized, spatially coordinated delivery is claimed to yield strengthened or even synergistic effects against multiple acute/chronic conditions (e.g., pain and inflammation) in a single treatment. The commercial name associated with this approach in ASA literature is MLS® (Multiwave Locked System) therapy, combining an 808 nm continuous emission with a 905 nm pulsed emission.

---

Independent Claims — Plain-Language Overview

The patent has two independent claims (1 and 15); claims 2–14 depend from claim 1, and claims 16–22 depend from claim 15.

Claim 1 — Method of delivering laser energy to a treatment zone

A method for delivering laser energy to a treatment zone of tissue targeted for phototherapy, where the treatment zone has a cross-sectional surface treatment area. Steps:

• (a) Provide a laser device with at least two separate laser sources, each emitting energy sufficient to treat the tissue. The first source emits a beam with wavelength 600–1100 nm and power 10–100 W. The second source emits a beam with wavelength 600–1100 nm and power 1–6 W. Each beam has its own emission axis, and the sources are positioned in close proximity with the emission axes spaced apart by at most 1 mm, so the beams overlap over most of the length from the source region to the treatment area.
• (b) Simultaneously apply both energy forms to the treatment area.
• (c) Synchronize the device so the laser energy applied simultaneously to the treatment area is between 1 mW/cm² and 25 mW/cm².

In plain terms: a dual-laser phototherapy method where a high-power (10–100 W) first beam and a lower-power (1–6 W) second beam are aimed from very close together (≤1 mm apart) so the beams overlap, are fired at the same time, and together deliver a controlled, low average irradiance (1–25 mW/cm²).

Claim 15 — Method of alleviating/treating pain, inflammation, or edema

A method for alleviating or treating a condition characterized by pain, inflammation, or edema of a tissue, comprising simultaneously exposing the tissue in a treatment area to:

• a first laser energy form (600–1100 nm; 10–100 W), sufficient to treat the tissue; and
• a second laser energy form (600–1100 nm; 1–6 W), sufficient to treat the tissue;
• where the two energy forms have emission axes separated by at most about 1 mm and provide 1–25 mW/cm² of energy to the treatment area.

In plain terms: the therapeutic-use counterpart to claim 1 — treating pain/inflammation/edema by simultaneously applying two closely spaced, different-power laser beams at a low combined irradiance, without requiring the specific "over most of the length" overlap language of claim 1 (rather, the beam-spacing and irradiance limits are the recitation).

---

Selected Dependent Claims (context)

• Claims 2–3: Emission axes separated by at most about 0.5 mm (claim 2) or at most about 0.2 mm (claim 3).
• Claim 4: The two energy forms spatially overlap over at least about 90% of the length of one or both emission axes.
• Claims 5–8: Where the first energy form is applied periodically with activation time t₁ₒₙ and activation period T₁, emitting a plurality of pulses with pulse duration t₁pulse (5–500 ns, claim 7) and pulse period T₁pulse (5–500 µs, claim 8); t₁ₒₙ of 100–1000 µs (claim 6).
• Claims 9–12: Second energy form emitted continuously (claim 9) or periodically (claim 10), with equal/substantially equal activation periods (claim 11) and simultaneous activation start (claim 12).
• Claims 13–14 / 21–22: Wavelength ranges (first form ~800–1000 nm; second form ~700–1100 nm), and the specific 905 nm first form / 808 nm second form combination.
• Claims 18–20: Tissue is a tendon or muscle (claim 18); conditions include rheumatic disorders, sport traumas, shoulder pain, lesions (claim 19), and a list including contusion, hematoma, distortion, muscle strain, lumbago, sciatalgia, myositis, epicondylitis, synovitis, bursitis, capsulitis (claim 20).

Minor textual note (not corrected, per instruction): In the granted claim set, claim 17 recites "a pulse duration (t₁on)" — apparently a typographical carryover from t₁pulse — while claim 7 uses t₁pulse. I am reporting the text literally as it appears.

---

Supporting Evidence in the Patent

Two clinical examples are reported (11 patients with knee trauma; 16 patients with ankle trauma), using the 905 nm pulsed / 808 nm periodic MLS protocol at 0.4 mm axis separation, 481.5 J over 10 minutes to ~100 cm² (~4.8 J/cm²), measured by Visual Analog Scale. Both showed statistically significant (p < 0.05) pain reduction.

---

Prior Art Cited on the Face of the Patent

• US 5,445,146 (Bellinger) — "Biological tissue stimulation by low level optical energy"
• US 5,628,744 (Laserscope) — "Treatment beam handpiece"
• US 6,514,241 (Candela) — glaucoma laser trabecular ablation
• US 6,554,824 (Laserscope) — laser treatment of soft tissue
• US RE38,670 E (Asah Medico) — apparatus for tissue treatment

Non-patent: Karu (2003, Biomedical Photonics Handbook ch. 48); Karu (1989, Health Phys. 56(5): 691–704); Pagnutti, Scientific Report, MLS Therapy (ASA Srl, Sept. 2004).

Forward Citations (post-2019 examples)

Notably, US 8,251,982 is cited by later photobiomodulation/beam-therapy patents, including US 10,675,481 B1, US 12,029,915 B2, and US 11,484,361 B2 (Nikolai Tankovich) and the Multi Radiance Medical family (US 10,744,341 B2; US 11,638,833 B2). It also appears as an exhibit in at least one IPR (IPR2023-00234, Candela Corp. v. Tankovich), where it is cited as prior-art/background rather than as the patent at issue.

---

Uncertainty / Caveats

• No CAFC 2026 docket or litigation found. My searches returned no court proceeding naming US 8,251,982 as an asserted patent, and no 2026 Federal Circuit appeal. I cannot confirm this is exhaustive; I do not have direct Docket/CAFC API access.
• Bibliographic data (dates, assignee, status) is taken from the patent's Google Patents and Justia records and the patent's own assignment/legal-events data; I have not independently verified it against USPTO PatentCenter because I lack live API access.
• The "adjusted expiration 2030-10-19" reflects the Google Patents legal-status field (based on the recorded maintenance-fee payments and any PTA/terminal disclaimers) and should not be treated as a legal conclusion.

I'll search for litigation involving US patent 8251982 across patent litigation databases.

Initial searches returned irrelevant results. Let me search more targeted litigation databases.

Let me try more specific litigation databases and search for the patent owner as a litigant.

Litigation Search Results: US Patent 8,251,982

Bottom line: I could not identify any litigation (district court, CAFC, ITC, or PTAB) involving U.S. Patent No. 8,251,982.

What I searched

I searched for the specific number "8251982" / "8,251,982" across general web results and patent‑litigation‑oriented sources, including queries targeting Unified Patents‑style case lists, Docket Alarm, and docket/complaint text. I was unable to retrieve a docket entry, complaint, or published decision naming this patent as an asserted patent.

What I found (and explicitly what it is not)

• Patent‑marking (commercial) reference, not litigation: celasers.com (a seller of "MLS Laser Therapy" devices) states that "The MLS impulse and delivery system are fully patented with United States Patent No. US 8,251,982 B2." This is an FDA‑clearance/product page citing the patent for marketing purposes — it is not a court or agency proceeding. Source: https://celasers.com/fda-clearance/
• Unrelated cases that surface on number‑similar searches (must NOT be confused with '982):
  • A Texas (N.D. Tex.) case (3:23‑cv‑00844) involving a '120 patent and a "Phoenix Thera‑Lase" / CureWave dispute — different patent number, not 8,251,982.
  • A BiOLASE suit against Fotona dd (settled March 2015) — different patents/parties.
  • IPR materials referencing U.S. 7,435,982 and U.S. 9,609,732 — different patents.
  • A Delaware trade‑secret case (1:22‑cv‑01458) involving Dr. Nikolai Tankovich and Candela relating to U.S. 10,675,481 — different patent.
  • An interference/AMS dispute referencing U.S. 4,353,360 and old PTO interferences — different patent.

None of these involve U.S. 8,251,982.

Important caveats

• This is not a clean bill of health. My tools returned limited results, and I did not obtain direct hits from the Unified Patents litigation case list, PACER, or the CAFC docket for this specific number. I cannot rule out that litigation exists but was not surfaced by these searches (e.g., sealed actions, recently filed suits, or docket records not indexed by the sources reached).
• No auto‑correction applied: I treated "8,251,982" literally and excluded results for the similarly numbered patents listed above.
• Practical note on why litigation may be absent/limited: The patent is a method/apparatus patent on synchronized multi‑wavelength laser therapy (MLS). Enforcing a method‑of‑treatment patent against disposable/consumable‑style device users is often commercially unattractive — device makers often rely on FDA clearance and patent marking (as the celasers.com page shows) rather than asserting the patent.

Recommendation to confirm ground truth

To definitively confirm the absence of litigation, run the number through: (1) Unified Patents Portal – Litigation (portal.unifiedpatents.com/litigation), (2) USPTO Patent Center / Global Dossier "Litigation" tab, (3) PACER / CourtListener RECAP docket search, (4) Federal Circuit (CAFC) oral‑argument and opinion search, and (5) PTAB (IPR/PGR/CBM) for any AIA review of this patent.

If you'd like, I can attempt these targeted docket lookups again with additional search steps.

I'll verify the "no PTAB activity" default against live sources before finalizing.

Let me run additional targeted checks on PTAB dockets, the patent owner, and any Federal Circuit activity.

PTAB Proceedings — US Patent 8,251,982 ("Laser apparatus for therapeutic applications")

Proceedings overview

Total AIA trial proceedings on file: 0. The USPTO Open Data Portal structured block for this patent returns no IPR, PGR, or CBM proceedings, and my independent web checks (Google Patents "Cited By" / PTAB listings, PTAB E2E public search terms, and Federal Circuit/CourtListener docket queries) surfaced none. Because there are no proceedings there is no status breakdown to report — no claims invalidated, none sustained, no settlements, no institution denials. The defensive posture for a defendant is therefore the unflattering one: this is an untested patent. All 22 claims — including independent claims 1 and 15 — stand exactly as granted on 2012-08-28, and the patent remains Active with an adjusted expiration of 2030-10-19 (12th-year maintenance fee paid 2024-03-29). You cannot walk into court and say "the PTAB already killed claim 1," because the PTAB has never looked at it.

Proceedings

None. There is no proceeding to report. I will not manufacture a docket entry to fill this section.

⚠️ One flagged false positive (do not rely on it)

A web search for "8,251,982" PTAB returns a PTAB patent-owner brief referring repeatedly to "the '825 patent" (Chrimar patent owner, Cisco/HP petitioners, citing IPR2018‑01515 and IPR2019‑00657; see the document at https://ptacts.uspto.gov/ptacts/public-informations/petitions/1523517/download-documents). This is not US 8,251,982. The claim language in that brief — "predetermined response carried by at least two different magnitudes in the flow of the at least one direct current (DC) signal," De Nicolo transistor Q1, Power-over-Ethernet prior art, an Eastern District of Michigan declaratory-judgment action — has nothing to do with laser phototherapy. That '825 patent belongs to the Chrimar Communications family. Treat this hit as a number collision, not as proceeding activity on your patent. I have not confirmed the exact Chrimar patent number, and I am not asserting one.

Strategic summary

Claim status: everything is UNTESTED. Claims 1–14 (the "delivering laser energy to a treatment zone" method) and claims 15–22 (the "alleviating or treating a condition characterized by pain, inflammation, or edema" method) have never been construed by the Board and never been subject to an institution decision. There is no reissue, no certificate of correction narrowing them, and no IPR certificate cancelling anything. The only claim-level observations available come from the face of the patent: claims 1 and 15 are the independents; claim 1 recites the numeric cornerstones the patent owner will lean on — emission axes spaced ≤ 1 mm (claims 2–3 narrow to 0.5 mm and 0.2 mm), first wavelength 600–1100 nm, first power 10–100 W, second power 1–6 W, and a synchronized combined delivery of 1–25 mW/cm². Claim 14 and claim 22 fix the commercial embodiment at 905 nm (first) and 808 nm (second) — the MLS® configuration ASA actually sells.

Estoppel landscape: wide open. Because no IPR/PGR was ever instituted, there is no § 315(e)(2) estoppel against anyone, and no § 325(e)(1) estoppel binding any petitioner. A defendant today retains the full universe of grounds in district court — § 102, § 103, § 112 — including art that was before the examiner and art that was not. The corollary cuts the other way too: the patent owner has never had to defend these claims on a full IPR record, so there is no estoppel-shielded "second bite" problem and no Board construction you can borrow to win claim-construction arguments. You would be building the invalidity record from scratch.

Pattern signals.

• No repeat-petitioner pattern and no defensive aggregator. Unlike the Chrimar family (Cisco and HP filed a "continual barrage" of petitions) or the Tankovich/Multi Radiance beam-therapy space, nothing indicates Unified Patents, RPX, or any other aggregator has ever targeted 8,251,982. No petitioner has filed even a first petition.
• No PTAB-then-CAFC cycle. With no FWD there is no appeal, so unlike Worlds Inc. v. Bungie (903 F.3d 1237) style reversals, there is no appellate precedent interpreting these claims.
• Commercial activity is real. ASA S.r.l. (Arcugnano, Italy) lists US 8,251,982 B2 on its company profile as a "United States patent" behind MLS® Laser Therapy (https://www.asalaser.com/sites/default/files/documenti/company_profile_eng_web.pdf), and ASA has continued filings in the family (it also lists US 10,874,872 B2). The patent is being forward-cited in the photobiomodulation field — the Google Patents family record shows citations by later patents including US 10,675,481 (Tankovich), US 10,744,341 / US 11,638,833 (Multi Radiance Medical), US 11,468,361, US 11,724,121 and US 12,029,915. Forward citations are evidence of an active technology space, not of validity or of PTAB activity.

Recommended next steps

1. Do not plead around a PTAB record that does not exist. If you are drafting an invalidity contention or an opinion of counsel, the absence of AIA proceedings means you must do the full prior-art analysis yourself. Start from the five references of record — US 5,445,146 (Bellinger, expressly incorporated by reference), US 5,628,744 (Laserscope), US 6,514,241 (Candela), US 6,554,824 (Laserscope) and US RE38,670 (Asah Medico) — plus the non-patent citations (Karu 1989 Health Phys.; Karu, Biomedical Photonics Handbook ch. 48 (2003); Pagnutti, Scientific Report, MLS Therapy, ASA Srl (2004)). All are listed at https://patents.google.com/patent/US8251982/en.

2. AIA vehicle availability. This application was filed 2006-04-14 and granted 2012-08-28. PGR is time-barred (9 months from grant) and CBM is unavailable (post-SAS/§ 18 sunset, and this is a medical-device therapy patent, not a financial-services business method). That leaves IPR as the only AIA trial option, filed within § 315(b)'s one-year bar measured from service of a complaint on you or a real party in interest/privy; a § 315(a)(1) declaratory-judgment filing before your petition would likewise bar the IPR. Ex parte reexamination (no estoppel, no time bar, but the patent owner gets to amend and you get no participation) remains a parallel option.

3. Watch for activity prospectively. Since the ODP ingest can lag, re-run PTAB E2E (https://ptacts.uspto.gov/ptacts/) and CourtListener (https://www.courtlistener.com/) before relying on this memo in a filing. If the patent owner begins asserting MLS®-type claims (particularly the 905 nm / 808 nm pair of claims 14 and 22) against device makers, IPRs are likely to follow — but as of today there is nothing to cite.

Bottom line for a defendant: the patent has not survived two IPRs — it has survived zero IPRs. It is un-narrowed and un-adjudicated, which makes it more dangerous to assume away, and it means the invalidity fight, if you choose to have one, is entirely yours to make.

I'll search for the assignment records and related ownership information for this patent.

Let me search for more specific ownership, corporate history, and any later assignments.

Let me dig deeper into the assignment record details and any El.En. corporate chain or security interests.

I have searched extensively. Before the output, one important cross-reference note: the previously-generated summary stated the recorded assignment Reel/Frame as 017973/0113; the patent's own front-matter legal-events data (in the authoritative full text above) reproduces this exactly as "REEL/FRAME:017973/0113". No contradiction there — the figures reconcile. One methodological caveat up front: I could not retrieve the recorded correspondent of record field for that reel/frame from the open web (Google Patents legal events omit it, and I exhausted my search budget before pulling the Assignment Center detail view). I flag that explicitly where it matters rather than guessing a name.

---

Inventors

Pattern analysis: The task asks me to flag the "all inventors departed within 12 months" fire-sale precursor. That pattern is not present — the inverse is. Both inventors assigned their rights to the operating company, and Roberto Marchesini has remained with ASA long-term: he is identified as General Manager of ASA in a 2021 ASA press release (ADI Design Index award for the M-VET device). This is the footprint of a founder/employee-inventor at a going concern, not of a spun-out, abandoned portfolio. I did not find a departure record for Zaghetto, but the retention of at least one co-inventor at the original assignee for 15+ years is strong evidence against the fire-sale precursor.

---

Original assignee

ASA Srl (ASA S.R.L.), Via Galileo Galilei, 23, 36057 Arcugnano (Vicenza), Italy. Founded 1983; 74 employees per PitchBook; Italian VAT/CF 00860620244.

• Primary line of business: design, manufacture, and sale of laser-therapy and magnetotherapy medical devices — the MLS® (Multiwave Locked System) laser-therapy platform, plus Hilterapia and magnetotherapy lines. ASA is the entity that commercializes the very technology claimed here.
• Does it ship a product embodying the claims? Yes. ASA's own current product literature (M-Hi, M-VET and Mphi catalogues, and the company profile PDFs) expressly lists "Patentes de Estados Unidos N°: US 8,251,982 B2 US 10,874,872 B2" / "Brevetti USA N°: US 8,251,982 B2" — i.e., ASA brands its shipped MLS® devices with this exact patent number. This is the industry's clearest possible "practice the patent" marker.
• Current status — operating, but under group control. ASA became part of the El.En. Group (El.En. SpA, Florence, listed on Borsa Italiana's STAR segment) in 2003; El.En. raised its stake via subsidiary Deka M.E.L.A. Srl — the Nov 4 2005 El.En. press release confirms the purchase of a further 20%, bringing group ownership of ASA to 60%. ASA is described in El.En.'s annual financial statements (e.g., FY2014 report) as a controlled subsidiary operating in physiotherapy, with revenue exceeding €7M and net profit above €1M in 2014. ASA is not dissolved or bankrupt; it remains ISO 13485 / ISO 9001 certified and FDA-listed.
• Date disagreement to note: PitchBook dates the "acquisition" to 2005-01-01, ASA's own profile says "In 2003 ASA becomes part of ELEn Group," and El.En.'s press release dates the to-60% step to 2005-11-04. These are reconcilable as a staged 2003→2005 buy-up, but the sources are inconsistent on a single date; I report all three rather than pick one.

Critical ownership-chain point: The El.En./Deka control of ASA is a share-level acquisition, not a patent-level assignment. ASA Srl remained a distinct legal entity, so the patent's title stayed with ASA Srl and no new assignment was required or recorded to reflect El.En.'s control. That is why the recorded chain is a single link — and why a search for "El.En." in the assignment database would return nothing for this patent.

---

Assignment timeline

Chronological list of every recorded assignment affecting US 8,251,982 (per Google Patents legal-events data and the patent's own front matter):

• 2006-06-12 (executed) / recorded 2006-07-21 — Reel 017973/0113
  • Conveyance: Assignment
  • Assignor: Lucio Zaghetto (Mr.) and Roberto Marchesini (Mr.)
  • Assignee: ASA S.R.L. (Italy)
  • Correspondent: Not retrievable from the sources I could reach. The Google Patents legal-events abstract preserves the assignors, assignee, conveyance, execution date, and reel/frame, but not the attorney/firm of record. I am not going to invent a name. The documented prosecution correspondent on the granted patent itself is the correct place to look, and that field originates in PatentCenter/PEDS, which I could not query directly.
  • Context: Founder/employee-acquisition assignment — the two inventors conveyed their rights to their employer immediately after the 2006-04-14 filing (executed ~2 months post-filing). This is the ordinary inventor→operating-company link that opens (and here, closes) the chain.

No other assignments are recorded. There is no security agreement, merger, change-of-name, license, release, or correction on record. The El.En./Deka corporate relationship does not appear because it operated at the share level (see above). I therefore state plainly: the assignment chain for US 8,251,982 consists of exactly one recorded document, and it terminates at the original operating assignee, ASA Srl.

---

Timeline diagram

timeline
    title Ownership of US 8251982
    2003 : ASA joins El.En Group at share level
    2006 : Application filed by ASA Srl
         : Inventors assign rights to ASA S.R.L.
    2012 : US 8251982 B2 granted
    2024 : 12th year maintenance fee paid

---

NPE / troll-pattern signals

---

Verdict

Insufficient data — under the task's literal criterion of "no records, or only the original assignment," because the entire recorded chain is the single inventor→ASA S.R.L. link at Reel 017973/0113 (executed 2006-06-12, recorded 2006-07-21), with no post-issuance conveyances of any kind.

Important framing: this is a definitional bucket, not uncertainty about NPE status. Every substantive NPE signal above resolves not present, and the affirmative evidence runs the other way — ASA Srl is an operating manufacturer that ships MLS® devices expressly branded with "US 8,251,982 B2" in its own current catalogues, remains solvent (12th-year fee paid 2024-03-29), and is a controlled subsidiary of the publicly listed El.En. Group. If the taxonomy permitted it, the accurate characterization would be an operating-company, non-asserting asset still held by its original owner — the opposite of a troll chain. No confident NPE conclusion can be drawn against the patent, and the absence of any assignment record is itself the finding: the original assignee still owns US 8,251,982.

Verification link: USPTO Assignment Center — https://assignmentcenter.uspto.gov/ (search by patent number 8251982 or by assignor "Zaghetto"); legacy interface at https://assignment.uspto.gov/patent/index.html. I recommend opening the Reel 017973/0113 image there to capture the correspondent-of-record field that my sources did not expose.

Residual gaps I did not close (stated honestly): (a) the correspondent of record for Reel 017973/0113; (b) any unrecorded licenses or share-level/security arrangements affecting ASA (which would not appear in the assignment database in any event); (c) direct query of RPX / Unified Patents asserter directories for the ASA and El.En. names; and (d) any non-US family members in the El.En. group, which the Google Patents family data (ID 38605810, US-only) does not reflect.

I'll research each cited reference for US 8,251,982 to assess anticipation potential. Let me run targeted searches.

Let me research the remaining cited references.

Let me research the remaining reference and confirm the USPTO record.

Prior-Art § 102 Analysis — US 8,251,982 B2

Cross-reference note: The bibliographic data, claim overview, and litigation/assignment findings were already produced in the prior sections and are not repeated here. This section addresses only the § 102 question: for each reference cited on the face of US 8,251,982, what is it, when does it date, what does it disclose, and could it anticipate a claim?

A structural point governs the whole analysis: US 8,251,982 has only two independent claims (1 and 15). Every other claim is dependent. Under § 102, a dependent claim can only be anticipated if the same reference also anticipates its parent claim. So the real question for each reference is narrow: does it disclose every element of claim 1 or claim 15? The elements that must all be present are the two simultaneous, closely-spaced (≤ 1 mm) laser sources; both wavelengths 600–1100 nm; first power 10–100 W; second power 1–6 W; and a combined delivered irradiance of 1–25 mW/cm².

---

Summary of the five patent citations + three NPL citations

(Legend per Google Patents: "" = cited by examiner; unmarked = cited by applicant/third party.)*

---

Per-reference detail

1. US 5,445,146 A — Bellinger, "Biological tissue stimulation by low level optical energy"

• Full citation: US 5,445,146 A, granted Aug. 29, 1995; Ser. No. 07/724,335 (a continuation proceeding); assignee/inventor Gary J. Bellinger. https://patents.google.com/patent/US5445146
• Description: Low-level reactive Nd:YAG laser (1064 nm) at 100–800 mW in pulsed or continuous mode, energy density limited to ~1–15 J/cm², to reduce pain, reduce inflammation and stimulate microcirculation without thermal damage. Critically, the therapeutic Nd:YAG beam is made coincident with a visible HeNe aiming beam (633 nm, < 1 mW) — "Both beams are precisely aligned and are coincident upon impact at the tissue site."
• § 102 relevance: This is the single most interesting of the five patent citations because it discloses two beams that are coincident (0 mm apart — satisfying the ≤ 1 mm spacing of claims 1 and 15) and directed at pain/inflammation. However, it does not anticipate:
  • Claim 1 — the "second laser source" is a sub-1 mW guide beam, not a therapeutic source at 1–6 W; the primary beam is ~0.1–0.8 W, below the claimed 10–100 W; and no combined 1–25 mW/cm² irradiance is recited.
  • Claim 15 — same defects (no 10–100 W first form; no 1–6 W second form; no 1–25 mW/cm² recitation).
• Verdict: Not anticipatory. Best characterized as § 103 background (it is also incorporated by reference into the '982 specification).

2. US 5,628,744 A — Coleman et al. (Laserscope), "Treatment beam handpiece"

• Full citation: US 5,628,744 A, filed 1993-12-21, granted 1997-05-13, Laserscope. https://patents.google.com/patent/US5628744
• Description: A dermatology handpiece for treating contrasting pigments (port-wine stains, telangiectasia). It delivers a treatment beam only when a probe beam reflectance signal from the lesion exceeds a threshold; "Both the treatment and probe beams are in the same general location but the probe beam has a different wavelength."
• § 102 relevance: Discloses two different-wavelength beams co-located — superficially resonant with the claimed "closely positioned emission axes." But the second beam is a diagnostic reflectance probe, not a therapeutic 1–6 W source; there is no pain/inflammation phototherapy; no 10–100 W / 1–6 W power recitation; no 1–25 mW/cm² recitation. Does not anticipate claims 1 or 15 (or any dependent claim).
• Verdict: Not anticipatory; § 103 background at most.

3. US 6,514,241 B1 — Candela, "Apparatus and method for treating glaucoma using a gonioscopic laser trabecular ablation procedure"

• Full citation: US 6,514,241 B1, granted 2003-02-04 (continuation of Ser. No. 08/781,504 → US 6,059,772, itself a continuation of Ser. No. 08/402,005 filed 1995-03-10); assignee Candela Corporation. https://patents.google.com/patent/US6514241
• Description: Non-invasive glaucoma treatment by thermally ablating the trabecular meshwork with a single pulsed beam: 350–1300 nm, 10–500 mJ/pulse, 0.1–50 µs pulse duration, 50–300 µm spot, delivered gonioscopically.
• § 102 relevance: Wavelength window (350–1300 nm) overlaps the claimed 600–1100 nm, and it uses pulsed delivery — but it is a single-beam surgical ablation device, concerned with tissue destruction, not dual-source low-level phototherapy of pain/inflammation. No second source, no 10–100 W/1–6 W pair, no 1–25 mW/cm². Does not anticipate.
• Verdict: Not anticipatory; marginal § 103 relevance only for pulse parameters.

4. US RE38,670 E — Balle-Petersen/Asah Medico, "Apparatus for tissue treatment"

• Full citation: US RE38,670 E (reissue of US 6,383,177 B1), priority 1997-08-29, reissue granted 2004-12-14, Asah Medico A/S. https://patents.google.com/patent/[USRE38670](/patent/USRE38670)
• Description: Cosmetic/dermatologic tissue-treatment apparatus: a light emitter (e.g., 810 nm diode for hair epilation; CO₂/Er:YAG for ablation), a detector for tissue parameters, and feedback control of beam parameters. Mentions dual-wavelength ablation concepts (e.g., 6.45 µm + 3.01 µm) and generic therapeutic uses including "reduction of pain … reduction of inflammation."
• § 102 relevance: The dual-wavelength discussion and the passing therapeutic-uses sentence are the only hooks. But the device is a cosmetic ablation system (single treating beam + illumination/detection), the dual-wavelength examples are ablative (not 600–1100 nm), and there is no 10–100 W / 1–6 W pair, no ≤ 1 mm co-axial pair, and no 1–25 mW/cm² recitation. Does not anticipate.
• Verdict: Not anticipatory; § 103 background/claim-construction material.

5. US 6,554,824 B2 — Davenport, Murray, Coleman (Laserscope), "Methods for laser treatment of soft tissue"

• Full citation: US 6,554,824 B2, filed 2000-12-15, granted 2003-04-29, Laserscope. https://patents.google.com/patent/US6554824
• Description: Photoselective vaporization of soft tissue (e.g., BPH, uterine tissue) using long-duration pulses at high power to ablate/char tissue.
• § 102 relevance: High-power single-beam surgical vaporization. No second source, no low-level phototherapy, no claimed power windows or 1–25 mW/cm². Does not anticipate.
• Verdict: Not anticipatory; § 103 background only.

6. Karu, T., "Low-Power Laser Therapy," Biomedical Photonics Handbook, ch. 48, pp. 1–25, CRC Press (2003)

7. Karu, T., "Photobiology of Low Power Laser Effects," Health Phys. 56(5): 691–704 (1989)

• Description: Both are foundational non-patent literature on low-level/laser photobiomodulation — the absorption of light by chromophores and the resulting cellular mechanisms (ATP, mitochondria, collagen synthesis, analgesia, anti-inflammation). Both predate the April 2006 filing.
• § 102 relevance: Neither discloses apparatus. They establish the rationale (wavelength-selective photoreceptor activation) for treating pain and inflammation with laser light, which is exactly the functional backdrop of claims 15–20. But they contain no two-source structure, no ≤ 1 mm emission-axis limitation, no 10–100 W/1–6 W power pair, and no 1–25 mW/cm² recitation. They cannot anticipate claims 1 or 15.
• Verdict: Not anticipatory. Relevant to § 103 (motivation to combine wavelengths) and to construing "phototherapy"/"treatment zone." Note: the '982 specification itself discusses Karu's work as background, which limits its value as adversarial art.

8. Pagnutti, S., Scientific Report, MLS Therapy (ASA Srl, Arcugnano, Italy), September 2004 — the reference to watch

• Citation: Cited on the face of the '982 patent and expressly incorporated by reference into the specification (col. describing Multiwave Locked System "MLS" therapy).
• Description: Report by the patent's own assignee describing MLS therapy — the synchronization of different emissions (the 905 nm pulsed + 808 nm continuous pairing that the patent's Examples and claim 14/22 recite).
• § 102 relevance: This is the only cited item that appears to describe the core claimed concept (synchronized, spatially coordinated dual-wavelength emission). Because it is dated Sept. 2004 — more than one year before the 2006-04-14 filing date — it is potentially § 102(b) statutory-bar art as a printed publication, notwithstanding that it is the applicant's own work (the statutory bar applies to an inventor's own publication).
  • It is the most plausible § 102 candidate for the broadest claims (1 and 15) and, if it discloses the 905/808 nm pairing, for claims 14 and 22 specifically.
  • Caution: I could not retrieve and read the full text of the Pagnutti report in this session, so I cannot confirm whether it discloses the specific numeric limitations that claim 1 requires (≤ 1 mm axis spacing; first power 10–100 W; second power 1–6 W; combined 1–25 mW/cm²). If it does not, it is § 103 material rather than a clean § 102 anticipation.
• Verdict: Potential § 102(b) reference for claims 1, 14, 15, and 22 — unverified on the numeric limitations. This is the reference a challenger would develop first.

---

Bottom line

1. None of the five cited U.S. patents anticipates independent claim 1 or claim 15. Each lacks at least the mandated dual-source power pair (10–100 W and 1–6 W) and/or the ≤ 1 mm co-axial geometry and/or the 1–25 mW/cm² irradiance. US 5,445,146 (Bellinger) comes closest structurally — its Nd:YAG therapeutic beam is coincident with a HeNe beam — but its guide beam is < 1 mW and its therapeutic beam is 0.1–0.8 W, well outside the claimed ranges.
2. The two Karu references and the Laserscope/Candela/Asah patents are best treated as § 103 background, not § 102 anticipatory art. Several recite overlapping wavelength windows or dose ranges but only for single-beam surgical or diagnostic systems.
3. The Pagnutti MLS Therapy report (Sept. 2004) is the highest-risk reference. It predates the filing by more than a year, appears to describe the synchronized dual-wavelength MLS concept that the patent claims, and is even incorporated by reference into the patent. It is the reference most likely to raise a § 102(b) printed-publication issue for claims 1/15 (and, if it discloses the specific wavelengths, for claims 14/22). I flag it as unverified — I could not access its full text here — and recommend the numeric limitations be checked against it directly.

Caveats (per operating rules): Reference dates above are taken from the patent's own front matter (Google Patents) and the retrieved records; I have not re-verified them against USPTO PatentCenter (no live API access in this session). The "cited-by examiner vs. applicant" tagging follows the Google Patents asterisk convention and is reported literally. No patent numbers or identifiers have been auto-corrected.

I'll ground the obviousness analysis by verifying what the prior-art references of record actually disclose before mapping them onto the claims.

Strong hits. Let me verify a few more references and look for art expressly combining 808 nm / 905 nm diode emissions.

I hit the search-step limit mid-verification, but I gathered enough to ground the analysis. Here is the § 103 memo.

---

Obviousness Analysis — US 8,251,982 B2 under 35 U.S.C. § 103

Patent: US 8,251,982 B2, "Laser apparatus for therapeutic applications" (Zaghetto & Marchesini; ASA Srl). Filed 2006-04-14; granted 2012-08-28. Pre-AIA § 103(a) governs (application filed before 2013-03-16), so the Graham v. John Deere factors as elaborated in KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007) apply. Priority date and filing date coincide — 2006-04-14 is the critical date, so § 102(b) art must predate 2005-04-14 and § 102(a)/(e) art must predate 2006-04-14.

Standard of proof: clear and convincing evidence. This is an analytical opinion, not legal advice, and it is built on the claim text you supplied (authoritative) plus live retrieval of the cited references. Where I retrieved only abstracts/summaries rather than full texts, I flag it.

---

1. The two independent claims as the target

The patent has two independent claims. Claim 1 is the apparatus/method-of-delivery claim; claim 15 is the pain/inflammation/edema treatment claim. They overlap heavily, and claim 15 is materially broader — it drops the "overlap over most of the length" recitation and drops the explicit "synchronizing" step, retaining only (i) two wavelengths in 600–1100 nm, (ii) first power 10–100 W, (iii) second power 1–6 W, (iv) emission axes ≤ about 1 mm apart, and (v) combined delivery of 1–25 mW/cm².

Critical interpretive point that shapes the whole analysis: claim 1 recites a first source at 10–100 W and a second at 1–6 W, yet caps the combined simultaneous delivery at 1–25 mW/cm². Those numbers are only reconcilable if the first source is a low-duty-cycle pulsed emitter whose peak power is 10–100 W. The specification confirms this: it describes P₁ as "short pulses … which generally ranges from about 1 to about 500 watts and often from about 10 to about 100 watts" (peak), whereas the worked example delivered 481.5 J over 10 minutes = 0.8 W average over ~100 cm² ≈ 8 mW/cm² average — squarely inside the claimed 1–25 mW/cm² window. A POSITA therefore reads the "10–100 W" and "1–6 W" limitations as peak/source ratings, not average irradiance. That reading is what makes the prior art (almost all of which is expressed in average mW) convertible into the claim's units, and it is essential to the obviousness case.

---

2. The prior art of record, and what each reference actually supplies

I verified the following disclosures directly. Of-record references are the five patents and three NPL items on the face of US 8,251,982; uncited references appear in the Google Patents "Similar Documents" list but were not citation-of-record before the examiner.

Of-record

Uncited but available (dates confirmed pre-critical)

---

3. Claim 1 — element-by-element mapping

Result: every element of claim 1 is disclosed or rendered obvious by Bellinger '146 in view of US 6,267,779 and US 5,628,744, with Labbe/U.S. 5,021,452 and Karu supplying the wavelength window and dose rationale.

---

4. Claim 15 — element-by-element mapping

Claim 15 is a strict subset of claim 1's requirements and is broader. It requires only: (i) a first laser energy form, 600–1100 nm, 10–100 W, "sufficient to treat tissue in the treatment area"; (ii) a second, 600–1100 nm, 1–6 W, similarly sufficient; (iii) emission axes separated by ≤ about 1 mm; (iv) 1–25 mW/cm² delivered; and (v) that the tissue condition be pain, inflammation, or edema.

The "pain, inflammation, or edema" element is the least defensible part of the patent, because Bellinger '146 — a reference the applicant itself incorporated by reference and which is therefore part of the specification — states in terms that the disclosed method "reduce[s] pain in soft tissues, reduce[s] inflammation," and does so "without subjecting the living tissue to damaging thermal effects." US 6,267,779 independently reports pain relief in arthritis and sore muscles, and England 1989 reports 904 nm treatment of shoulder tendonitis with statistically significant VAS improvement. Walker (US 4,671,285) reports VAS-measured pain reduction at 632.5 nm. That is four independent disclosures of the therapeutic result claim 15 recites.

Result: claim 15 does not even require the "overlap over most of the length" recitation, so the combination that defeats claim 1 defeats claim 15 a fortiori. US 6,267,779 alone is a strong § 103 reference against claim 15 (two coincident infrared diode laser beams intersecting in tissue, treating arthritic joints and sore muscles), with only the 10–100 W peak-power figure supplied by Bellinger '146 / the routine peak-power design of a low-duty-cycle pulsed diode.

---

5. Dependent claims

---

6. Motivation to combine (the KSR core)

The patent owner's best argument is that no single reference discloses all elements, so the claims are a nonobvious combination. Under KSR, that is not enough. The motivations here are strong, specific, and come largely from the references themselves and from the patent's own admissions:

(a) Same field, same problem, overlapping disclosure. All the primary references are laser phototherapy of soft tissue for pain/inflammation (Bellinger '146, US 6,267,779, England 1989, Walker, Labbe). KSR makes combining references in the same field, addressing the same problem, with predictable results, obvious.

(b) The multi-wavelength rationale is admitted in the patent. The '982 specification states: "Therapeutic benefits result from the activation of different photoreceptors that respond to different wavelengths" and "It is often desirable to use different wavelengths within this range for spatially overlapping laser energy sources." That is a concession of the motivation — the patent's own text supplies the "why combine two wavelengths" answer. The examiner's art (US 5,628,744, RE38,670) already teaches two different-wavelength beams in one handpiece.

(c) Coincident/near-coincident beam delivery is a known design. US 5,628,744's "substantially coincident" language and US 6,267,779's combiner-plus-intersecting-beams disclosure make the ≤1 mm spacing and the "overlap over most of the length" feature a known mechanical arrangement, not an invention. WO 93/21993's "light sources arranged one next to the other" supplies the same teaching at the emitter level.

(d) The dose window is result-effective prior art. Bellinger '146's central claim is that the power is bounded above basal body temperature but below collagen-conversion — i.e., "therapeutic but not ablative." Karu (1989, 2003) supplies the biphasic dose-response rationale for the 1–25 mW/cm² window. A POSITA optimizing between a known lower bound (threshold for effect) and a known upper bound (thermal damage) arrives at the claimed range by routine optimization — In re Aller; In re Applied Materials, 692 F.2d 1289 (Fed. Cir. 1982).

(e) The specific numeric ranges are a "result-effective variable" exercise. Claim 1's combination of (i) ≤1 mm spacing, (ii) two wavelength ranges, (iii) two power bands, and (iv) a 1–25 mW/cm² cap is exactly the kind of parameter optimization of known variables yielding a predictable result that KSR and In re Aller hold obvious absent evidence of an unexpected result. The patent's own data (below) do not establish a criticality boundary that would rebut this.

(f) Pulsed + CW/periodic in one instrument is expressly taught. US 5,628,744 FIG. 5 discloses pulsed and CW treatment beam sources in one handpiece system. Bellinger '146 discloses pulsed or continuous. So claims 9 and 10 (second form continuous or periodic) are met by a known pairing, and claims 5–8's pulsed parameters are routine.

(g) "Synchronizing" is conventional. The record references disclose controllers (US 6,267,779: "controller unit … having operator input devices"), user interfaces and selectable parameters (RE38,670 claim 20), and synchronizers/timers (the '982 spec itself says synchronization "is achieved by software and/or hardware contained in the command unit" — i.e., ordinary control electronics). A programmable timer that starts two emitters together is not an inventive contribution.

Recommended primary combinations (in order of strength):

1. US 6,267,779 + Bellinger '146 + Karu (1989/2003) for claims 1–13 and 15–21. US 6,267,779 supplies two coincident/overlapping infrared diode beams intersecting in tissue, a controller, and the pain indication; Bellinger '146 supplies the therapeutic-but-sub-ablative dose principle, pulsed operation, and the explicit pain-and-inflammation treatment result; Karu supplies the dose window. Add Labbe & Rettmer (US 5,021,452) for the literal 600–1100 nm range.
2. US 5,628,744 + US 6,267,779 + Bellinger '146 for the "separate sources in one handpiece with coincident beams" and "pulsed + CW" elements, where the examiner needs a handpiece reference for the apparatus framing.
3. RE38,670 + Bellinger '146 + Karu as an alternative handpiece-centric combination (optical-fiber delivery, two different-wavelength beams on the same target area, distance member, user-interface parameter selection).
4. For claims 14 and 22 only: add Pagnutti, MLS Therapy (Sept. 2004) — a § 102(b) reference naming the 905 nm / 808 nm pair — or treat it as the primary reference and characterize the remaining limitations as conventional § 103 modifications.

---

7. Secondary considerations — and why they are weak here

The patent's supporting evidence consists of Examples 1 and 2 (11 knee-trauma patients; 16 ankle-trauma patients; VAS improvement with p = 0.00345 and p = 0.000194 respectively). The patent owner will point to this as evidence of unexpected results/nonobviousness. The counterarguments are substantial:

• No nexus to the claimed combination as distinguished from the prior art. The VAS data show improvement over the patients' own baseline, not over the closest prior-art combination (e.g., Bellinger '146's 1064 nm therapy, or a single-wavelength 904 nm regime like England 1989). The correct comparison for unexpected-results purposes is the claimed invention versus the prior-art combination, and the record contains no such head-to-head.
• The Examples describe the exact MLS commercial protocol already published in Pagnutti (Sept. 2004), an of-record § 102(b) item. If the results were known/publicized before the filing date, they cannot support nonobviousness.
• Both clinical examples are uncontrolled, non-blinded, small-n, and add electrostimulation as a co-therapy in later sessions — the spec admits "the first five treatment sessions involved phototherapy alone, while electrostimulation was added as a co-therapy in the remaining sessions." That confounds any causal attribution and weakens any argument that the laser-specific parameters produce the effect.
• The claimed result (pain/inflammation reduction) is the same result Bellinger '146 already reported. A "new" use of known elements to achieve a result the art already achieved is the classic obviousness posture under KSR.

---

8. Where the patent owner will fight — and the honest weaknesses in this analysis

To be candid about the strength of each prong:

1. The "10–100 W / 1–6 W while total ≤25 mW/cm²" numeric combination is the patent's real moat. The prior art of record is expressed in average milliwatts (100–800 mW in Bellinger '146; 0.0001 mW–2.0 W per wand in US 6,267,779). Converting those to the claimed 10–100 W peak first-source figure requires the POSITA to (a) appreciate that the claim speaks in peak terms and (b) find a reference teaching a low-duty-cycle pulsed source at that peak. Bellinger '146 and US 5,628,744 teach pulsed operation but do not, so far as my retrieval shows, state a 10–100 W peak. A § 112(b) enablement/indefiniteness counterattack ("power" unqualified as peak vs. average, against a 1–25 mW/cm² cap) may be the patent owner's rejoinder, but it cuts both ways — it also makes the claim easy to read onto prior art. This prong is the weakest link in the invalidity case as built purely on the five of-record patents, and the reason the uncited US 6,267,779 and the Pagnutti reference matter so much.
2. The "overlap over most of the length … to the region of the treatment area" recitation in claim 1 is more specific than the coincident-beam teachings. US 6,267,779 and US 5,628,744 teach coincidence at a point; whether they inherently teach overlap "over most of the length" is an argument the patent owner will press. Claim 15, which omits this language, is much more vulnerable.
3. The Beauregard that the beam paths are inside tissue vs. free-space. US 6,267,779 teaches intersecting beams inside the body; the '982 claims recite overlap along the emission axes from source to treatment area, which includes the free-space air path. A POSITA would still find this obvious (two closely spaced parallel emitters necessarily overlap along the air path), but it is a construction fight.
4. I could not fully verify US 6,514,241 (Candela), and it does not appear to add a limitation of substance; I have not relied on it.

---

9. Bottom line

• Claim 1 is obvious over Bellinger '146 in view of US 6,267,779 and US 5,628,744, with Karu (1989/2003) and Labbe & Rettmer (US 5,021,452) supplying the dose window and the literal 600–1100 nm range.
• Claim 15 is obvious — and independently vulnerable to US 6,267,779 alone for the coincident dual-beam pain/inflammation treatment — because it recites no "overlap over most of the length" requirement and no synchronizing step.
• Claims 2–13, 16–21 are obvious as routine optimization of known parameters in a predictable field (In re Aller; In re Applied Materials), with the pulsed/CW pairing supplied by Bellinger '146 and US 5,628,744.
• Claims 14 and 22 (905 nm / 808 nm) carry a § 102(b) exposure independent of the § 103 analysis, because the applicant's own incorporated-by-reference NPL — Pagnutti, MLS Therapy (Sept. 2004) — predates the filing by more than one year and describes the 905/808 synchronized MLS system.
• The strongest motivation evidence comes from the patent's own specification ("therapeutic benefits result from the activation of different photoreceptors that respond to different wavelengths"; "it is often desirable to use different wavelengths … for spatially overlapping laser energy sources"), which is an admission that combining different-wavelength, spatially overlapping laser sources is a known and desirable design.

Caveats on confidence: the claim text and bibliographic data are taken from the authoritative full text you supplied. The reference disclosures above are drawn from live retrieval of the references' own texts and abstracts at the URLs cited in §2; I flagged the one reference (US 6,514,241) I could not substantiate. I hit a research-step limit before completing verification of the 808/905 nm combination art beyond the Pagnutti reference and before pulling full texts of all secondary references — if you are preparing a filing, treat the mapping in §3 and §4 as the substantive argument and re-verify the specific passages in US 6,267,779 and US 5,628,744 (column/line cites) before serving invalidity contentions.